A review. Importance: Currently, there is no unified framework linking disease progression to established viral levels, clin. tests, inflammatory markers, and investigational treatment options. Objective: It may take many weeks or months to establish a standard treatment approach. Given the growing morbidity and mortality with respect to COVID-19, the authors present a treatment approach based on a thorough review of scholarly articles and clin. reports. The authors' focus is on staged progression, clin. algorithms, and individualized treatment. Evidence Review: the authors followed the protocol for a quality review article proposed by Heyn et. al. A literature search was conducted to find all relevant studies related to COVID-19. The search was conducted between Apr. 1, 2020 and Apr. 13, 2020 using the following electronic databases: PubMed (1809 to present), Google Scholar (1900 to present), MEDLINE (1946 to present), CINAHL (1937 to present), and Embase (1980 to present). Keywords used included COVID-19, 2019-nCov, SARS-CoV-2, SARS-CoV, and MERS-CoV, with terms such as efficacy, seroconversion, microbiol., pathophysiol., viral levels, inflammation, survivability, and treatment and pharmacol. No language restriction was placed on the search. Reference lists were manually scanned for addnl. studies. Findings: Of the articles found in the literature search, 70 were selected for inclusion in this study (67 cited in the body of the manuscript and 3 addnl. unique references in the Figures). The articles represent work from China, Japan, Taiwan, Vietnam, Rwanda, Israel, France, the United Kingdom, the Netherlands, Canada, and the United States. Most of the articles were cohort or case studies, but the authors also drew upon information found in guidelines from hospitals and clinics instructing their staff on procedures to follow. In addition, the authors based some decisions on data collected by agencies such as the CDC, FDA, IHME, ISDA, and Worldometer. None of the case studies or cohort studies used a large number of participants. The largest group of participants numbered less than 500 and some case studies had fewer than 30 patients. However, the review of the literature revealed the need for individualized treatment protocols due to the variability of patient clin. presentation and survivability. A number of factors appear to influence mortality: the stage at which the patient first presented for care, pre-existing health conditions, age, and the viral load the patient carried. Conclusion and Relevance: COVID-19 can be divided into three distinct Stages, beginning at the time of infection (Stage I), sometimes progressing to pulmonary involvement (Stage II, with or without hypoxemia) and less frequently to systemic inflammation (Stage III). In addition to modeling the stages of disease progression, the authors' have also created a treatment algorithm which considers age, comorbidities, clin. presentation, and disease progression to suggest drug classes or treatment modalities. This paper presents the first evidence-based recommendations for individualized treatment for COVID-19.